BioMimetic Therapeutics (BMTI)
BioMimetic Therapeutics Earnings Per Share: -0.22
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
BMTI Earnings Per Share Rankings
| Overall | 10th percentile | 3977 of 4458 |
| Sector | 19th percentile | 410 of 511 in Healthcare |
| Industry | 9th percentile | 60 of 66 in Medical Instruments & Supplies |
BMTI Earnings Per Share Range, Past 5 Years
| Minimum | -0.97 | Sep 2008 |
| Maximum | 1.62 | Mar 2008 |
| Average | -0.264 |
About Earnings per Share
Earnings per share (EPS) the amount of income that "belongs" to each share of common stock. An important tool for investors, EPS is often used in determining the value of a stock.
The average number of shares outstanding (the denominator of the EPS formula) is usually calculated by averaging the number of shares at the beginning of the earning period and the number of shares at the end of the period. For example, if a company earned $1 million in 2009 and had 900,000 shares at the beginning of 2009 and 1.1 million shares at the end of 2009, the 2009 EPS would be $1 million/[(.9 million shares + 1.1 million shares)/2] = $1/share.
EPS is generally reported in annualized form from the most recent fiscal year. From time to time, you will see the abbreviation (ttm) associated with earnings per share. That means that the earnings number is a sum of the previous four quarters, which is not necessarily the same as the previous fiscal year.
Learn More
You may also be interested in these BMTI related companies
BMTI News
Listen to $BMTI Q1 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/3kfu
about 15 days ago by earningscast
about 15 days ago by earningscast
BioMimetic Therapeutics, Inc. Reports First Quarter 2012 Earnings Results
May 09, 4:00PM Business Wire
May 09, 4:00PM Business Wire
BioMimetic Therapeutics, Inc. to Report First Quarter 2012 Financial Results on May 9
May 07, 11:00AM Business Wire
May 07, 11:00AM Business Wire
BioMimetic (BMTI) Shares Rallying on Very Heavy Volume, Stock Now Up Nearly 7%
Apr 04, 1:53PM Street Insider
Apr 04, 1:53PM Street Insider
@ACInvestorBlog $BMTI - what developments do you see that might move this stock up or down? And forget about insider purchases.
about 52 days ago by gregthor
about 52 days ago by gregthor
Listen to $BMTI Q4 2011 earnings call - live at 04:30 PM, ondemand after - http://stks.co/2pPl
about 72 days ago by earningscast
about 72 days ago by earningscast
BioMimetic Therapeutics, Inc. (BMTI) Posts Wider than Expected Q4 Loss
Mar 13, 4:00PM Street Insider
Mar 13, 4:00PM Street Insider
BioMimetic Therapeutics, Inc. Reports Fourth Quarter and Year-End 2011 Earnings Results
Mar 13, 4:00PM Business Wire
Mar 13, 4:00PM Business Wire
BioMimetic Therapeutics, Inc. to Report 2011 Fourth Quarter and Year-End Financial Results on March 13
Mar 09, 2:27PM Business Wire
Mar 09, 2:27PM Business Wire
$BMTI http://stks.co/2kdZ Look For A Move Over The Range Break And Then 50 EMA At 2.24.
about 77 days ago by XiATH
about 77 days ago by XiATH
BioMimetic Therapeutics, Inc. to Introduce Augmatrix™ Biocomposite Bone Graft Product Line at AAOS
Feb 08, 9:25AM Business Wire
Feb 08, 9:25AM Business Wire
$BMTI too risky. Strong Buys $SINO,target $6 $ONTY $OCZ lots of room to run
about 108 days ago by contrarian1
about 108 days ago by contrarian1
Collins Stewart Reiterates a 'Buy' on BioMimetic Therapeutics (BMTI); Positive Pilot Study Offer Another Sizable Opportunity
Feb 07, 11:05AM Street Insider
Feb 07, 11:05AM Street Insider
BioMimetic Therapeutics, Inc. to Highlight Product Development Activities at ORS and AAOS Meetings
Feb 06, 4:00PM Business Wire
Feb 06, 4:00PM Business Wire
BioMimetic Therapeutics, Inc. to Present at the 30th Annual J.P. Morgan Healthcare Conference
Jan 10, 11:00AM Business Wire
Jan 10, 11:00AM Business Wire
Wedbush Downgrades BioMimetic Therapeutics (BMTI) to Neutral, Still See Approval of Augment Bone Graft
Jan 04, 12:18PM Street Insider
Jan 04, 12:18PM Street Insider
$BMTI BioMimetic Therapeutics downgraded to Neutral from Outperform at Wedbush
about 142 days ago by _TheBlackSwan_
about 142 days ago by _TheBlackSwan_
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| BMTI | 2.41 | +0.10 | +4.33% | 64.98M |
| BMRN | 38.51 | +0.47 | +1.24% | 4.398B |
| BMR | 18.42 | +0.05 | +0.27% | 2.833B |
| BLTI | 2.37 | +0.01 | +0.42% | 72.43M |
| BLL | 39.86 | +0.33 | +0.83% | 6.180B |
| BKSC | 11.37 | -0.63 | -5.25% | 50.60M |
| BKR | 22.62 | +0.09 | +0.40% | 214.94M |
| BKMU | 3.52 | +0.03 | +0.86% | 161.69M |
| BKK | 16.22 | +0.12 | +0.75% | |
| BKH | 31.72 | -0.04 | -0.13% | 1.400B |
